Hope Is Not A Plan: Manufacturing COVID-19 Therapeutics
Duke-Margolis discussion emphasizes biopharma sector must quickly collaborate on manufacturing coronavirus therapeutics likely to be authorized or approved in coming months.
You may also be interested in...
Companies are shielded from antitrust concerns by Justice Department as they jointly prepare to manufacture whichever monoclonal-antibody-based coronavirus therapies emerge from development.
Ability to quickly scale manufacturing is a key criteria for Operation Warp Speed therapeutics, but for monoclonal antibodies the most effective approach may mean fewer doses. FDA’s Janet Woodcock said the government is supporting a range of antibody approaches for COVID-19 so that if virus escape mutants emerge from single antibody treatment there will be other options, while Regeneron argues the cocktail approach is safer, even though it will likely mean fewer doses of drug will be available.
David Ricks says a consortium of companies will be needed to ensure enough doses of the successful candidates are available.